Stock Movers AstraZeneca Climbs, Philips Soars, Stellantis Falls
Jul 29, 2025
AstraZeneca shares soared 2% after reporting impressive second-quarter earnings, impressing analysts with a strong sales beat. Philips is on the upswing too, raising its profitability outlook amid concerns over trade wars. In contrast, Stellantis is struggling, with shares down 3.4% as it faces a hefty €1.5 billion tariff impact projected for 2025. These financial shifts highlight the contrasting fortunes of major companies in today's market.
AI Snips
Chapters
Transcript
Episode notes
AstraZeneca's Growth Strategy
- AstraZeneca's strong Q2 was driven by a focused bet on cancer medicines and US market expansion.
- The success hinges on a potential blockbuster drug, Datraway, whose study results have been delayed to next year.
Philips' Earnings Outlook Reversal
- Philips reversed its earnings outlook after finding the trade war impact was less severe than feared.
- This turnaround occurred within just two months, boosting investor confidence.
Stellantis Tariff Challenges
- Stellantis faces significant tariff-related losses with €1.2 billion expected in H2, lowering its operating margin guidance.
- Continued tariff uncertainty is expected to challenge the car sector despite new trade deals.